Kigali on; 14/04/2021 RefNº: DIS/ 1256/FDA/2021



RWANDA FDA Rwanda Food and Drugs Authority P.O. Box 1948 Kigali info@rwandafda.gov.rw www.rwandafda.gov.rw

District Pharmacies (All) Referral Hospitals (All) District Hospitals (All) Central medical stores (All) Pharmaceutical Wholesalers (All) Importers (All) Retail Pharmacies (All)

<u>Re:</u> Recall for a batch of Erythromycin Estolate Oral Suspension USP 125mg/5ml (AGOMYCIN)

Reference is made to the Law N° 003/2018 of 09/02/2018 establishing Rwanda Food and Drugs Authority especially in its article 8 paragraph 2 and 13.

Reference is also made to the Laboratory quality control test report within the routine Post Marketing Surveillance activities;

Rwanda FDA recalls the following batch of Erythromycin Estolate Oral Suspension USP 125mg/5ml (AGOMYCIN) that was found out of specification for the content of Erythromycin Estolate, from the market;

2019 Oct.2022 AGOG Pha India	arma Limited,
India	
	attin atting
nd Drugs Auth	ority
	nd Drugs Auth

Action to be taken

- Rwanda Food and Drugs Authority instructs all importers, central medical stores, wholesalers, District Pharmacies, retailers, Public and Private Health Facilities to stop the distribution of the above incriminated batch of Erythromycin Estolate Oral Suspension USP 125mg/5ml (AGOMYCIN) and return them to the suppliers for suitable management.
- The importers and Suppliers of the incriminated batch of Erythromycin Estolate Oral Suspension USP 125mg/5ml/AGOMYCIN are requested to report to Rwanda FDA within 10 working days, the quantities imported, quantities distributed, quantities returned and final stock on hand

Note: For more information or to report any suspected poor quality products please call 0789193529 or send email to: <u>pv_sm@rwandafda.gov.rw</u>

You will find pictures of the recalled medicine as attachment.

Sincerely,

Dr. Charles KARANGWA Ag. Director General

RWANDA FDA Rwanda Food and Drugs Authority

